GENFIT Announces Half-Year Liquidity Contract Report with Crédit Industriel et Commercial

GENFIT, a late-stage biopharmaceutical company specializing in liver diseases, has released its half-year report for its liquidity contract with Crédit Industriel et Commercial as of June 30, 2024. According to the report, the liquidity account held 131,000 shares and €700,885.51.

During the first half of 2024, GENFIT engaged in transactions involving 1,515,865 shares for €5,499,002.56 on the buy side and 1,532,677 shares for €5,669,272.79 on the sell side. The number of executed trades totaled 2,256 on the buy side and 2,012 on the sell side.

At the beginning of the contract, the liquidity account contained 27,911 shares and €769,849.43. This summary provides insight into the financial activities managed through the liquidity contract with Crédit Industriel et Commercial over the last six months.